could it be big pharma is looking toward other treatments/drugs under development in the cancer space, hence see a shorter life expectancy in current drugs
over the last 3 year the big end of town have had lots of M&A, with different style of drug etc
would take alot of DYOR to establish what this different direction are ... and expected life of current applicantions,
any idea on alternatives
Ann: DEP irinotecan clinical data presented at AACR meeting, page-13
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.31M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.9¢ | $14.97K | 151.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 372123 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 5042 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| SPL (ASX) Chart |